What topics does this cannabis study cover?

This study covers research on: Cancer.

Where was this research published?

Published in Clinical therapeutics on May 17, 2026.

Cancer

Legal cannabis remarkably free from mold toxins, study shows

Mycotoxin Trends of Cannabis Compliance Testing in Cannabis Flower and Concentrates in the United States.

Clinical therapeutics • May 17, 2026 • Moderately Relevant

🤖

AI Summary

This large-scale analysis examined mycotoxin contamination in regulated cannabis products across 11 US states, analyzing over 328,000 cannabis flower samples and 114,500 concentrate samples. Researchers assessed compliance with regulatory testing requirements for dangerous molds—specifically aflatoxins (B1, B2, G1, G2) and ochratoxin A—that can pose serious health risks to consumers. The findings reveal remarkably low failure rates of just 0.016% for flower and 0.017% for concentrates, indicating that regulated cannabis products in legal markets are largely free from mycotoxin contamination at levels that trigger regulatory action limits.

The study identified significant variation in how different laboratories reported mycotoxin detection, with some facilities reporting disproportionately high detection rates. When these outlier laboratories were excluded from analysis, adjusted detection rates dropped dramatically to approximately 0.1% for flower and 0.12% for concentrates, compared to initial reported rates of 3.28% and 8.32% respectively. Ochratoxin A emerged as the most frequently detected mycotoxin across both product types, though even these detections rarely exceeded safety thresholds.

These findings suggest that consumers purchasing cannabis from regulated legal markets face minimal exposure to mycotoxin contaminants under current compliance testing protocols. However, the researchers note an important caveat: current mycotoxin testing panels may not reflect the most relevant contamination risks in cannabis products, suggesting that future surveillance efforts should evaluate whether testing protocols need adjustment to better protect consumer health.

📄 Original Abstract

Regulatory testing for mycotoxins in cannabis is widely implemented, yet little is known about the prevalence and failure rates of regulated mycotoxins in legal markets at scale. This study aimed to characterize detection and failure rates for aflatoxins (B1, B2, G1, and G2) and ochratoxin A in regulated cannabis flower and concentrates using multi-state compliance testing data. State-level cannabis compliance testing data were obtained from 11 US states through public records requests and public data portals. The dataset included results for cannabis flower and concentrates submitted by licensed laboratories to state regulatory systems. Records associated with noncompliance testing, validation studies, superseded entries, or clear data entry errors were excluded. Detection and failure rates were calculated by product type and analyte. To assess the influence of laboratory-level reporting differences, analyses were repeated after excluding laboratories with unusually high mycotoxin detection frequencies. Across 328,682 flower samples and 114,579 concentrate samples, overall failure rates were low (0.016% for flower and 0.017% for concentrates). Ochratoxin A was the most frequently detected mycotoxin in both matrices, though detections rarely exceeded regulatory action limits. Reported detection rates across all laboratories were 3.28% for flower and 8.32% for concentrates. After excluding laboratories with disproportionately high detection rates, adjusted detection frequencies declined to approximately 0.1% for flower and 0.12% for concentrates. These findings indicate that regulated mycotoxins currently included in cannabis compliance panels occur infrequently and rarely exceed action limits in legal markets. Surveillance data suggests that consumer exposure under typical compliance conditions to these analytes is limited. Future surveillance efforts may benefit from evaluating whether current mycotoxin panels reflect the most relevant risk drivers in cannabis products.